Huihui Li
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 01, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: March 19, 2026
Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: January 19, 2026
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
Journal: Cancer communications (London, England)
Published: December 09, 2025
Dalpiciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial.
Journal: Nature cancer
Published: April 25, 2025
Efficacy and Safety of Anlotinib-Based Regimens in Metastatic Breast Cancer: A Multicenter Real-World Study.
Journal: Journal of evidence-based medicine
Published: April 24, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.
Journal: Nature communications
Published: October 11, 2024
An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial.
Journal: Cancer communications (London, England)
Published: June 12, 2024
TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer.
Journal: Science translational medicine
Published: April 03, 2024
Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Journal: Clinical and translational medicine
Published: January 24, 2024
Identification of significant single-nucleotide polymorphisms associated with breast cancer recurrence and metastasis using GWAS.
Journal: Cancer innovation
Published: January 03, 2024
Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
Journal: BMC cancer
Published: October 18, 2023
Last Updated: 09/26/2026